<?xml version="1.0" encoding="UTF-8"?>
<p>Foscarnet (phosphonoformic acid, PFA) has broad-spectrum antiviral activity against DNA and RNA viruses, including retroviruses. It is FDA-approved for the treatment of HIV-associated cytomegalo and herpes simplex virus infections in humans [
 <xref rid="B67-vetsci-02-00456" ref-type="bibr">67</xref>]. Foscarnet is usually administered intravenously by continuous intravenous infusion because of its short half-life, which has also been demonstrated in cats [
 <xref rid="B68-vetsci-02-00456" ref-type="bibr">68</xref>]. Oral administration of the drug is possible but can result in irritation of mucous membranes and oral bleeding. Foscarnet has many side effects, including nephrotoxicity and myelosuppression, in both humans and cats. It also is toxic to epithelial cells and mucous membranes, resulting in gastrointestinal side effects and genital epithelium ulceration. In addition, it chelates various cations, which can lead to hypocalcemia, hypomagnesemia, and hypokalemia [
 <xref rid="B69-vetsci-02-00456" ref-type="bibr">69</xref>,
 <xref rid="B70-vetsci-02-00456" ref-type="bibr">70</xref>].
</p>
